This document focuses on new ways to treat cancer using immunotherapy.
This Policy Review in The Lancet Oncology summarizes a National Cancer Institute Clinical Imaging Steering Committee workshop held on April 6, 2021, entitled Harnessing Imaging Tools to Guide Immunotherapy Trials. It brings together imaging experts and oncologists to review diagnostic imaging tools and response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials.
The review covers standard-of-care imaging such as CT, magnetic resonance, and FDG-PET, along with criteria including RECIST, iRECIST, and iRANO. It also examines investigational approaches such as radiomics, functional MRI agents, and novel molecular-imaging PET agents, and outlines paths for validating these tools through prospective trials or retrospective data analysis.
The meeting was convened to document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging.
The virtual meeting entitled Harnessing Imaging Tools to Guide Immunotherapy Trials was held on April 6, 2021.
The review covers the utility of CT, magnetic resonance, and F-fluorodeoxyglucose (FDG)-PET for assessing immunotherapy.